Related references
Note: Only part of the references are listed.Evolving pancreatic cancer treatment: From diagnosis to healthcare management
Michele Milella et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management
Daniel Schreyer et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
Annalisa Comandatore et al.
DIAGNOSTICS (2022)
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment
Lenka N. C. Boyd et al.
SEMINARS IN CANCER BIOLOGY (2022)
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma
Yasuyuki Mizutani et al.
BMC CANCER (2022)
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells
Cristina P. R. Xavier et al.
DRUG RESISTANCE UPDATES (2022)
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Nick Lung-Ngai Ting et al.
GUT (2022)
c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
Jingjing Yao et al.
FRONTIERS IN PHARMACOLOGY (2022)
A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
Christian Chapa-Gonzalez et al.
LIFE-BASEL (2022)
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
Jing-Quan Wang et al.
DRUG RESISTANCE UPDATES (2021)
Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer
Zongting Gu et al.
CANCER LETTERS (2021)
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Marina Macchini et al.
CANCER TREATMENT REVIEWS (2021)
Anticancer drug resistance: An update and perspective
Ruth Nussinov et al.
DRUG RESISTANCE UPDATES (2021)
Catechol enhances chemo- and radio-sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells
Jeong Yong Moon et al.
ONCOLOGY REPORTS (2021)
Optimizing the quality of clinical studies on oral microbiome: A practical guide for planning, performing, and reporting
Egija Zaura et al.
PERIODONTOLOGY 2000 (2021)
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das et al.
DRUG RESISTANCE UPDATES (2021)
Pancreatic Cancer and Gut Microbiome-Related Aspects: A Comprehensive Review and Dietary Recommendations
Bartosz Kamil Sobocki et al.
NUTRIENTS (2021)
Therapeutic potential of microbial modulation in pancreatic cancer
Vidhi Chandra et al.
GUT (2021)
The microbiome and human cancer
Gregory D. Sepich-Poore et al.
SCIENCE (2021)
Microbiome Markers of Pancreatic Cancer Based on Bacteria-Derived Extracellular Vesicles Acquired from Blood Samples: A Retrospective Propensity Score Matching Analysis
Jae Ri Kim et al.
BIOLOGY-BASEL (2021)
Microbiome and cancer
Nyssa Cullin et al.
CANCER CELL (2021)
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Camilla Pecoraro et al.
DRUG RESISTANCE UPDATES (2021)
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems
Elisa Giovannetti et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
The biological underpinnings of therapeutic resistance in pancreatic cancer
Gregory L. Beatty et al.
GENES & DEVELOPMENT (2021)
Cancer: a mirrored room between tumor bulk and tumor microenvironment
Pablo Hernandez-Camarero et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Chirayu Mohindroo et al.
CANCER MEDICINE (2021)
Tumor restriction by type I collagen opposes tumor- promoting effects of cancer-associated fibroblasts
Sonakshi Bhattacharjee et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Laura L. Meijer et al.
ANNALS OF SURGERY (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?
Audrey Frances et al.
MOLECULAR THERAPY (2020)
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
Srinivasa P. Pothula et al.
PANCREATOLOGY (2020)
Nanomedicine to target multidrug resistant tumors
Elise Lepeltier et al.
DRUG RESISTANCE UPDATES (2020)
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
Aadra P. Bhatt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The human tumor microbiome is composed of tumor type-specific intracellular bacteria
Deborah Nejman et al.
SCIENCE (2020)
Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment
Stephen H. Kasper et al.
SCIENTIFIC REPORTS (2020)
Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma
Kousik Kesh et al.
MICROBIAL CELL FACTORIES (2020)
Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Gregory D. Poore et al.
NATURE (2020)
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer
Robert W. Corty et al.
ONCOLOGIST (2020)
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
Hiroo Imai et al.
JOURNAL OF ONCOLOGY (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study
Michael Guenther et al.
BRITISH JOURNAL OF CANCER (2020)
Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro
Jianfei Xu et al.
LIFE SCIENCES (2020)
Open Sesame?: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer
Ornella Randazzo et al.
CANCERS (2020)
A framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai et al.
NATURE REVIEWS CANCER (2020)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The double edge sword of fibrosis in cancer
Chelsea Chandler et al.
TRANSLATIONAL RESEARCH (2019)
Pharmacogenetics of treatments for pancreatic cancer
Btissame El Hassouni et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
Omidreza Firuzi et al.
CANCERS (2019)
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells
Manoj Amrutkar et al.
BMC CANCER (2019)
Cancer-associated fibroblasts-heroes or villains?
Krystyna A. Gieniec et al.
BRITISH JOURNAL OF CANCER (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update
Alok A. Khorana et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Ela Elyada et al.
CANCER DISCOVERY (2019)
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
Yasuyuki Mizutani et al.
CANCER RESEARCH (2019)
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Erick Riquelme et al.
CELL (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
Xuan-Zhang Huang et al.
ONCOIMMUNOLOGY (2019)
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
Claire Vennin et al.
NATURE COMMUNICATIONS (2019)
Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, ...but do they contradict themselves?
Laura L. Meijer et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer
Sheng Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
Cindy Neuzillet et al.
JOURNAL OF PATHOLOGY (2019)
Tumor-Stroma IL1 beta-IRAK4 Feedforward Circuitry DrivesTumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
Daoxiang Zhang et al.
CANCER RESEARCH (2018)
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Adam J. Camblin et al.
CLINICAL CANCER RESEARCH (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Microbiome promotes pancreatic cancer
Iain Dickson
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
Smruti Pushalkar et al.
CANCER DISCOVERY (2018)
The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer
Lu Yuan et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Bacterial infections and cancer
Daphne van Elsland et al.
EMBO REPORTS (2018)
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Adrian C. Jaramillo et al.
CANCER DRUG RESISTANCE (2018)
TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1
P-H Huang et al.
ONCOGENE (2017)
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
K. E. Richards et al.
ONCOGENE (2017)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
The role of stromal cancer-associated fibroblasts in pancreatic cancer
Dagny von Ahrens et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Leore T. Geller et al.
SCIENCE (2017)
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
E. Giovannetti et al.
SEMINARS IN CANCER BIOLOGY (2017)
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
Kit Man Wong et al.
CURRENT ONCOLOGY REPORTS (2017)
Probiotic strain Lactobacillus casei BL23 Prevents colitis-associated colorectal cancer
Elsa Jacouton et al.
FRONTIERS IN IMMUNOLOGY (2017)
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Stefano Coppola et al.
DRUG RESISTANCE UPDATES (2017)
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients
Katsuya Makihara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
TaChung Yu et al.
CELL (2017)
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Cristoforo Grasso et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Not only P-glycoprotein: Amplification of the &ITABCB1&IT-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins
Ilaria Genovese et al.
DRUG RESISTANCE UPDATES (2017)
Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics
Aurian P. Garcia-Gonzalez et al.
CELL (2017)
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis
Guozhe Xian et al.
CANCER LETTERS (2017)
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
Rachel A. Hesler et al.
CARCINOGENESIS (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment
Tessa Y. S. Le Large et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Loss of the DNA Damage Repair Kinase ATM Impairs Inflammasome-Dependent Anti-Bacterial Innate Immunity
Saskia F. Erttmann et al.
IMMUNITY (2016)
5-Fluorouracil sensitivity varies among oral micro-organisms
Eline Vanlancker et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2016)
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
Harrison Kim et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Faiyaz Notta et al.
NATURE (2016)
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
Andrew H. Ko et al.
PANCREAS (2016)
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Chiara Caparello et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
Maarten F. Bijlsma et al.
CANCER AND METASTASIS REVIEWS (2015)
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2015)
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Yoav Binenbaum et al.
DRUG RESISTANCE UPDATES (2015)
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumourchemoresistance
Camille Duluc et al.
EMBO MOLECULAR MEDICINE (2015)
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
M. Sinn et al.
EUROPEAN JOURNAL OF CANCER (2015)
Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model
Q.-F. Gui et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice
Jingtao Hu et al.
JOURNAL OF BIOSCIENCES (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice
Silvia H. S. P. Pedroso et al.
MICROBIOLOGY-SGM (2015)
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer
Feng Cao et al.
ONCOLOGY REPORTS (2015)
TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas
Mie Grunnet et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces
Egija Zaura et al.
MBIO (2015)
Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
Hui Zhang et al.
ONCOTARGET (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs
Johan Vande Voorde et al.
FEBS OPEN BIO (2015)
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
S. Pant et al.
ANNALS OF ONCOLOGY (2014)
Pancreatic Cancer Stroma: Friend or Foe?
Jesse Gore et al.
CANCER CELL (2014)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Mara H. Sherman et al.
CELL (2014)
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Edward J. Kim et al.
CLINICAL CANCER RESEARCH (2014)
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
Albrecht Neesse et al.
GUT (2014)
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
S. Mitsunaga et al.
BRITISH JOURNAL OF CANCER (2013)
Stromal expression of SPARC in pancreatic adenocarcinoma
Cindy Neuzillet et al.
CANCER AND METASTASIS REVIEWS (2013)
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
Amir Avan et al.
CANCER RESEARCH (2013)
Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner
Thomas A. Mace et al.
CANCER RESEARCH (2013)
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
Minoti V. Apte et al.
GASTROENTEROLOGY (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back
Amir Avan et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression
Surabhi Dangi-Garimella et al.
PLOS ONE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
Genetically Engineered Mouse Models of Pancreatic Cancer
Christoph Benedikt Westphalen et al.
CANCER JOURNAL (2012)
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Maha Elnaggar et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Tetrahydrouridine Inhibits Cell Proliferation through Cell Cycle Regulation Regardless of Cytidine Deaminase Expression Levels
Naotake Funamizu et al.
PLOS ONE (2012)
CLASI-FISH: Principles of combinatorial labeling and spectral imaging
Alex M. Valm et al.
SYSTEMATIC AND APPLIED MICROBIOLOGY (2012)
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Chen Sun et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
Pancreatic stellate cells: a starring role in normal and diseased pancreas
Minoti V. Apte et al.
FRONTIERS IN PHYSIOLOGY (2012)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2
Surabhi Dangi-Garimella et al.
CANCER RESEARCH (2011)
Modulation of NF-κB signalling by microbial pathogens
Masmudur M. Rahman et al.
NATURE REVIEWS MICROBIOLOGY (2011)
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Bret D. Wallace et al.
SCIENCE (2010)
Multicomponent drug efflux complexes: architecture and mechanism of assembly
Helen I. Zgurskaya
FUTURE MICROBIOLOGY (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Vitamin K Prevents Oxidative Cell Death by Inhibiting Activation of 12-Lipoxygenase in Developing Oligodendrocytes
Jianrong Li et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2009)
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
Wu Huanwen et al.
MOLECULAR CANCER (2009)
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
Romano Danesi et al.
PHARMACOGENOMICS (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis
Yehuda G. Assaraf
DRUG RESISTANCE UPDATES (2006)
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
MG Kelly et al.
CANCER RESEARCH (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)
Basis for effective combination cancer chemotherapy with antimetabolites
GJ Peters et al.
PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
